Stevanato Group S P A Stock Price, News & Analysis

Stevanato Group (NYSE: STVN) announced it will release its Q1 2023 financial results on May 4, 2023, at 6:30 a.m. (ET). Following the release, a conference call will be held at 8:30 a.m. (ET) the same day, where management will discuss the results. Interested parties can pre-register for a conference passcode to gain immediate access or join via dial-in numbers provided for the United States, Italy, and United Kingdom.

The company will also provide a webcast of the discussion live, which will be archived for three months on its Investor Relations website. Stevanato Group, founded in 1949, is renowned for its solutions in drug containment and delivery across the pharmaceutical and life sciences sectors.

Stevanato Group (NYSE: STVN) has partnered with Thermo Fisher Scientific to introduce an innovative on-body drug delivery system. This semi-reusable device allows for micro-precision dosing and bolus injections, enhancing patient adherence by facilitating at-home administration of pharmaceuticals. The collaboration promises an end-to-end solution, combining Stevanato's EZ-fill® cartridges with Thermo Fisher's fill-and-finish services. This partnership not only accelerates time-to-market but also supports sustainability through reduced waste. Both companies aim to improve patient access to critical medications while meeting market demands swiftly.

Stevanato Group S.p.A. (NYSE: STVN) has announced a strategic collaboration with Recipharm, aiming to develop pre-fillable syringes for use in Recipharm’s soft mist inhalers. This partnership leverages Stevanato's 70+ years of manufacturing experience. The Alba^® syringes will integrate with Recipharm's Pre-Filled Syringe Inhaler (PFSI^TM) technology, enhancing drug delivery for sensitive products. The combined offering promises efficient respiratory delivery and improved containment solutions for biopharma companies. This collaboration underscores Stevanato's commitment to supporting drug development from clinical phases to market release.

Stevanato Group (NYSE: STVN), a global provider of drug containment and delivery solutions, announced its participation in the Virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21 and March 22, 2023. The company will present on March 21 at 11:15 a.m. ET, with a live audio webcast available on their website. A replay will be accessible for approximately 90 days post-event. Founded in 1949, Stevanato Group offers an integrated portfolio of products and services across the drug life cycle, emphasizing research, technical innovation, and engineering excellence.

Stevanato Group (NYSE: STVN) reported strong financial results for Q4 and FY 2022 and provided guidance for FY 2023. Q4 revenue rose 26% to €292.1 million, while FY 2022 revenue increased 17% to €983.7 million. Adjusted diluted EPS for Q4 were €0.19, and for FY 2022, €0.56. The company anticipates FY 2023 revenue between €1.085 billion and €1.115 billion and adjusted EPS of €0.58 to €0.62. Committed backlog grew 9% YoY to €957 million. Positive momentum was noted in high value solutions, accounting for 30% of revenue, with increased capital investments planned in the U.S. to meet demand.

Stevanato Group (NYSE: STVN) will release its fourth quarter and fiscal year 2022 financial results on March 2, 2023, at 6:30 a.m. ET. A conference call and webcast will follow at 8:30 a.m. ET, featuring a slide presentation available on the company’s Investor Relations site. Participants are encouraged to pre-register for expedited access. Dial-in options include +39 02 802 09 11 (Italy), +44 1 212 818004 (UK), and +1 718 705 8796 (USA). A replay of the webcast will be accessible for three months post-event, further enhancing transparency regarding the company’s performance.